Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008987 | 0.90 | ABCB1 (0.42) | TP53POLBMAPTTAAR1MEN1 | |
| SCHEMBL2008990 | 0.82 | ABCB1 (0.39) | ABCB1CYP3A4ALOX15 | |
| SCHEMBL3583727 | 0.82 | ABCB1 (0.38) | ABCB1CYP3A4ALOX15 | |
| SCHEMBL2869709 | 0.79 | TP53 (0.47) | TP53POLBMAPTTAAR1MEN1 | |
| SCHEMBL2009194 | 0.79 | TP53 (0.47) | TP53POLBMAPTTAAR1MEN1 | |
| SCHEMBL2878491 | 0.77 | TP53 (0.49) | TP53POLBMAPTTAAR1MEN1 | |
| SCHEMBL2878493 | 0.77 | TP53 (0.42) | TP53TAAR1PARP1LMNATRPV1 | |
| SCHEMBL2013291 | 0.75 | TP53 (0.47) | TP53POLBMAPTTAAR1MEN1 | |
| SCHEMBL3601953 | 0.75 | ABCB1 (0.43) | ABCB1CYP3A4ALOX15 | |
| SCHEMBL2010054 | 0.75 | TP53 (0.47) | TP53POLBMAPTTAAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | CBR1, CBR3, CYP2C9 | TP53 4332/4885POLB 3805/4885MAPT 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.